As proud partners of Breast Cancer Ireland we are pleased to see a €5million research programme focussing on metastatic breast cancer has been announced, aiming to improve outcomes for breast cancer patients. Glanbia has been a long time supporter of Breast Cancer Ireland's pioneering research into metastatic disease and it is heartening to see this collaborative research project receive significant state funding. This is good news for patients and good news for families.
A new €5 million research programme focused on advanced breast cancer has been announced today, aiming to improve survival rates and quality of life for patients with this challenging form of breast cancer. The PRISM (Precision Oncology Research Initiative for Metastatic Breast Cancer) programme, brings together research scientists from collaborating universities, a pharmaceutical company and Breast Cancer Ireland, and will be led by Professor Leonie Young, as Director and Dr Damir Vareslija as Co-Director, both from the Beaumont RCSI Cancer Centre. Breast Cancer Ireland is one of the lead partners of this pioneering 4 year research project into metastatic disease (alongside Research Ireland Strategic Partnership Programme and Carrick Therapeutics) with BCI having invested €1.8m of funding into the programme as part of our ongoing #MetastaticMatters campaign. Pictured at the announcement were (left-right): Aisling Hurley, CEO Breast Cancer Ireland; Dr Damir Vareslija, PRISM Co-Director; Prof. Leonie Young, Scientific Director of the Beaumont RCSI Cancer Centre and PRISM Director, Minister Patrick O’Donovan TD; Dr Aisling McEvoy, Head of Enterprise Partnerships at Research Ireland; Claire Noonan, COO Beaumont RCSI Cancer Centre; and Seamus Browne, Head of Industry Partnerships at RCSI. Picture: Jason Clarke Photography